Detection of short-chain fatty acids in biological samples
AssigneeHemaquest Pharmaceuticals, Inc.
InventorsRonald J. Berenson, Patrick Bobbitt, Zhongping Lin
Life of this patent
Estimating the term…
Abstract
Described herein is a method of detecting and/or quantifying analytes, such as short-chain fatty acids. Analysis for the presence and/or quantity of the small molecule can be performed on a biological sample from a subject. In some embodiments, a liquid chromatography/mass spectrometry (LC-MS/MS) instrumentation is combined with a solid-phase extraction (SPE). Methods of derivatization can also be incorporated with LC-MS/MS and SPE instrumentation to detect and quantify target analytes. In addition to derivation, methods of reconstituting derivatized molecules can also be incorporated with LC-MS/MS and SPE instrumentation to detect and quantify target analytes.
Claims25
A method for detecting or quantifying a short-chain fatty acid in a biological sample from a subject, comprising:
- a) purifying the short-chain fatty acid by removing at least a portion of non-short-chain fatty acid components of the sample, wherein the purifying step comprises subjecting the sample to solid phase extraction;
- b) chemically derivatizing said purified short-chain fatty acid;
- c) subjecting said derivatized product to mass spectrometry;
- and
- d) determining the presence or quantity of the derivatized product, thereby detecting or quantifying said short-chain fatty acid in said sample.
A method of monitoring treatment in a subject receiving a therapeutic short-chain fatty acid, comprising:
- a) purifying a short-chain fatty acid from said subject, wherein said purifying comprises subjecting said sample to solid phase extraction;
- b) chemically derivatizing said purified short-chain fatty acid;
- c) subjecting said derivatized product to mass spectrometry;
- d) determining the presence or quantity of the derivatized product, thereby quantifying said therapeutic short-chain fatty acid in said sample;
- and
- e) using the data collected from step d) to make a clinical decision.
The method of claim 19, wherein said cell proliferative disorder is cancer or cytopenia.
Dependencies are inferred from the claim text.